Alternatives for reducing relapse rate when switching from natalizumab to fingolimod in multiple sclerosis.
Fragoso YD, Adoni T, Alves-Leon SV, Apostolos-Pereira SL, Araujo YR, Becker J, Brooks JBB, Correa EC, Damasceno A, Damasceno CAA, Ferreira MLB, Gama PDD, Gama RADD, Gomes S, Goncalves MVM, Grzesiuk AK, Machado SCN, Matta APDC, Mendes MF, Ribeiro TAGJ, Rocha CFD, Ruocco HH, Sato H, Simm RF, Tauil CB, Vasconcelos CCF, Vieira VLF.
Fragoso YD, et al. Among authors: vieira vlf.
Expert Rev Clin Pharmacol. 2016 Apr;9(4):541-546. doi: 10.1586/17512433.2016.1145053. Epub 2016 Feb 21.
Expert Rev Clin Pharmacol. 2016.
PMID: 26794493